Economic Burden of Pneumonia in an Employed Population
Although the direct costs for treating pneumonia are known to be high, employers may be significantly underestimating the total financial burden of pneumonia, especially by overlooking the indirect (spill-over or shared) costs. This observation is meaningful clinically, as well, in terms of treatments for other problems that are related to the pneumonia.

Medical, pharmaceutical, and disability claims data were used to determine the annual per capita cost of pneumonia for beneficiaries of a Fortune 100 company. These costs were compared with a random sample of beneficiaries without pneumonia from the same employee population.

  • Annual costs for the pneumonia patients were about 5X other workers
  • The majority of the pneumonia-related costs was in about 10% of the patients
  • For every $1 spent on pneumonia health care costs, the employer spent another $12 on direct and indirect costs related to the worker's pneumonia

Conclusion: failure to properly account fully for these broader consequences of pneumonia could result in a significant underassessment of the cost of pneumonia to employers.

Birnbaum HG, Morley M, Greenberg PE, Cifaldi M, Colice GL. Economic Burden of Pneumonia in an Employed Population Arch Intern Med. December 10/24, 2001;161(22):2725-2731


Promising Research Findings for Clinicians--Pneumonia Prediction Model
Every year, about 600,000 of the 4 million Americans who develop community-acquired pneumonia (CAP) are hospitalized. However, because of a dearth of evidence-based admission criteria, coupled with a common tendency to overestimate the risk of death, many low-risk patients could safely be treated as outpatients and instead are admitted for more costly inpatient care.

The investigators of this study suggest that if the Fein protocol of model had been used, "26-31% of the patients who were hospitalized for care could have been treated safely as outpatients, and an additional 13-19% could have been hospitalized only briefly for observation." The investigators made projections from a prospective cohort study of 2,287 CAP patients in Pittsburgh, Boston, and Halifax, Nova Scotia, and they validated the model for accuracy and general applicability with data on over 50,000 CAP patients in 275 U.S. and Canadian hospitals."

For Consumers: More Patients Can Be Treated at Home

References: a partial list of studies from the Pneumonia PORT [AHCPR #97-R031, Jan 1997] (shown in reverse chronological order):
Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. The New England Journal of Medicine 1997 (January 23); 336:243-250.
Fine MJ, Hough LJ, Medsger AR, et al. The hospital admission decision for patients with community-acquired pneumonia: Results from the Pneumonia PORT. Archives of Internal Medicine 1997 (January 13); 157:36-44.
Fine MJ, Medsger AR, Stone RA, et al. The hospital discharge decision for patients with community-acquired pneumonia: Results from the Pneumonia PORT. Archives of Internal Medicine 1997 (January 13); 157:47-56.
Coley CM, Li YH, Medsger AR, et al. Preferences for home versus hospital care among low-risk patients with community-acquired pneumonia. Archives of Internal Medicine 1996 (July 22); 156:1565-1571.
Minogue MF, Hough LJ, Fine MJ, et al. Patients hospitalized after initial ambulatory therapy for community-acquired pneumonia. Journal of General Internal Medicine 1996 (April); 11(supplement 1):52A.
Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: A meta-analysis. The Journal of the American Medical Association 1996 (January 10); 275:2.
Cassiere & Fein - in Medscape 1(9),1997